228 related articles for article (PubMed ID: 31005427)
1. Efficient influenza A virus production in high cell density using the novel porcine suspension cell line PBG.PK2.1.
Gränicher G; Coronel J; Pralow A; Marichal-Gallardo P; Wolff M; Rapp E; Karlas A; Sandig V; Genzel Y; Reichl U
Vaccine; 2019 Nov; 37(47):7019-7028. PubMed ID: 31005427
[TBL] [Abstract][Full Text] [Related]
2. Influenza A virus production in a single-use orbital shaken bioreactor with ATF or TFF perfusion systems.
Coronel J; Behrendt I; Bürgin T; Anderlei T; Sandig V; Reichl U; Genzel Y
Vaccine; 2019 Nov; 37(47):7011-7018. PubMed ID: 31266669
[TBL] [Abstract][Full Text] [Related]
3. Semi-perfusion cultures of suspension MDCK cells enable high cell concentrations and efficient influenza A virus production.
Bissinger T; Fritsch J; Mihut A; Wu Y; Liu X; Genzel Y; Tan WS; Reichl U
Vaccine; 2019 Nov; 37(47):7003-7010. PubMed ID: 31047676
[TBL] [Abstract][Full Text] [Related]
4. Continuous influenza virus production in a tubular bioreactor system provides stable titers and avoids the "von Magnus effect".
Tapia F; Wohlfarth D; Sandig V; Jordan I; Genzel Y; Reichl U
PLoS One; 2019; 14(11):e0224317. PubMed ID: 31689309
[TBL] [Abstract][Full Text] [Related]
5. High cell density cultivations by alternating tangential flow (ATF) perfusion for influenza A virus production using suspension cells.
Genzel Y; Vogel T; Buck J; Behrendt I; Ramirez DV; Schiedner G; Jordan I; Reichl U
Vaccine; 2014 May; 32(24):2770-81. PubMed ID: 24583003
[TBL] [Abstract][Full Text] [Related]
6. Production of high-titer human influenza A virus with adherent and suspension MDCK cells cultured in a single-use hollow fiber bioreactor.
Tapia F; Vogel T; Genzel Y; Behrendt I; Hirschel M; Gangemi JD; Reichl U
Vaccine; 2014 Feb; 32(8):1003-11. PubMed ID: 24269322
[TBL] [Abstract][Full Text] [Related]
7. Serum-Free Suspension Culture of MDCK Cells for Production of Influenza H1N1 Vaccines.
Huang D; Peng WJ; Ye Q; Liu XP; Zhao L; Fan L; Xia-Hou K; Jia HJ; Luo J; Zhou LT; Li BB; Wang SL; Xu WT; Chen Z; Tan WS
PLoS One; 2015; 10(11):e0141686. PubMed ID: 26540170
[TBL] [Abstract][Full Text] [Related]
8. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
[TBL] [Abstract][Full Text] [Related]
9. High cell density perfusion process for high yield of influenza A virus production using MDCK suspension cells.
Wu Y; Bissinger T; Genzel Y; Liu X; Reichl U; Tan WS
Appl Microbiol Biotechnol; 2021 Feb; 105(4):1421-1434. PubMed ID: 33515287
[TBL] [Abstract][Full Text] [Related]
10. Comparison of influenza virus yields and apoptosis-induction in an adherent and a suspension MDCK cell line.
Peschel B; Frentzel S; Laske T; Genzel Y; Reichl U
Vaccine; 2013 Nov; 31(48):5693-9. PubMed ID: 24113260
[TBL] [Abstract][Full Text] [Related]
11. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.
Genzel Y; Dietzsch C; Rapp E; Schwarzer J; Reichl U
Appl Microbiol Biotechnol; 2010 Sep; 88(2):461-75. PubMed ID: 20617311
[TBL] [Abstract][Full Text] [Related]
12. Comparison of immunogenicity of cell-and egg-passaged viruses for manufacturing MDCK cell culture-based influenza vaccines.
Shin D; Park KJ; Lee H; Cho EY; Kim MS; Hwang MH; Kim SI; Ahn DH
Virus Res; 2015 Jun; 204():40-6. PubMed ID: 25892718
[TBL] [Abstract][Full Text] [Related]
13. Mathematical model of influenza A virus production in large-scale microcarrier culture.
Möhler L; Flockerzi D; Sann H; Reichl U
Biotechnol Bioeng; 2005 Apr; 90(1):46-58. PubMed ID: 15736163
[TBL] [Abstract][Full Text] [Related]
14. Perfusion Control for High Cell Density Cultivation and Viral Vaccine Production.
Nikolay A; Bissinger T; Gränicher G; Wu Y; Genzel Y; Reichl U
Methods Mol Biol; 2020; 2095():141-168. PubMed ID: 31858467
[TBL] [Abstract][Full Text] [Related]
15. High-cell-density cultivations to increase MVA virus production.
Vázquez-Ramírez D; Genzel Y; Jordan I; Sandig V; Reichl U
Vaccine; 2018 May; 36(22):3124-3133. PubMed ID: 29433897
[TBL] [Abstract][Full Text] [Related]
16. High titer MVA and influenza A virus production using a hybrid fed-batch/perfusion strategy with an ATF system.
Vázquez-Ramírez D; Jordan I; Sandig V; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2019 Apr; 103(7):3025-3035. PubMed ID: 30796494
[TBL] [Abstract][Full Text] [Related]
17. Performance of an acoustic settler versus a hollow fiber-based ATF technology for influenza virus production in perfusion.
Gränicher G; Coronel J; Trampler F; Jordan I; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2020 Jun; 104(11):4877-4888. PubMed ID: 32291490
[TBL] [Abstract][Full Text] [Related]
18. Development of suspension adapted Vero cell culture process technology for production of viral vaccines.
Shen CF; Guilbault C; Li X; Elahi SM; Ansorge S; Kamen A; Gilbert R
Vaccine; 2019 Nov; 37(47):6996-7002. PubMed ID: 31288997
[TBL] [Abstract][Full Text] [Related]
19. [Adherent and single-cell suspension culture of Madin-Darby canine kidney cells in serum-free medium].
Huang D; Zhao L; Tan W
Sheng Wu Gong Cheng Xue Bao; 2011 Apr; 27(4):645-52. PubMed ID: 21848001
[TBL] [Abstract][Full Text] [Related]
20. Impact of cultivation conditions on N-glycosylation of influenza virus a hemagglutinin produced in MDCK cell culture.
Rödig JV; Rapp E; Bohne J; Kampe M; Kaffka H; Bock A; Genzel Y; Reichl U
Biotechnol Bioeng; 2013 Jun; 110(6):1691-703. PubMed ID: 23297157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
